This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease
Signal Transduction and Targeted Therapy Open Access 02 October 2023
-
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Molecular Cancer Open Access 19 February 2019
-
Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis
Medical Microbiology and Immunology Open Access 01 November 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Manning BD, Cantley LC . AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261–1274.
Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin III E et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest 2004; 84: 235–244.
Gulmann C, Espina V, Petricoin III E, Longo DL, Santi M, Knutsen T et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 2005; 11: 5847–5855.
Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 2008; 7: 3265–3274.
Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108: 4156–4162.
Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122–1128.
Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007; 109: 2165–2173.
Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006; 134: 145–156.
Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851–1863.
Gibbons JJ, Abraham RT, Yu K . Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009; 36 (Suppl 3): S3–S17.
Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009; 106: 268–273.
Elenitoba-Johnson KS, Jenson SD, Abbott RT, Palais RA, Bohling SD, Lin Z et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003; 100: 7259–7264.
Acknowledgements
This work was supported by NIH grant RO1-CA096500 and UCRF funding to BD, and funding from the Leukemia and Lymphoma society (6021) and the AIDS malignancy consortium to DD. BD is a Leukemia and Lymphoma Society Scholar and a Burroughs Wellcome Fund Investigator in Infectious Disease. We acknowledge Novartis for providing us with NVP-BEZ235. We thank Charlene Ross and the Animal Studies core for their help. We thank Drs Thomas Shea and Kristy Richards as well as members of the Damania and Dittmer labs for helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Bhende, P., Park, S., Lim, M. et al. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 24, 1781–1784 (2010). https://doi.org/10.1038/leu.2010.154
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.154
This article is cited by
-
Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease
Signal Transduction and Targeted Therapy (2023)
-
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Molecular Cancer (2019)
-
Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis
Medical Microbiology and Immunology (2019)
-
Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma
Journal of Experimental & Clinical Cancer Research (2016)
-
Constitutive AKT activation in follicular lymphoma
BMC Cancer (2014)